Using Dupixent and UVB therapy for treating atopic dermatitis
Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis
PHASE4 · Psoriasis Treatment Center of Central New Jersey · NCT05285839
This study is testing if combining a medication called Dupixent with UVB light therapy can help people with moderate to severe eczema feel better.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Psoriasis Treatment Center of Central New Jersey (other) |
| Drugs / interventions | dupilumab |
| Locations | 1 site (East Windsor, New Jersey) |
| Trial ID | NCT05285839 on ClinicalTrials.gov |
What this trial studies
This is a 24-week open-label study that investigates the effectiveness of dupilumab combined with narrowband UVB phototherapy for patients with moderate to severe atopic dermatitis. Participants will receive the combination treatment three times a week for the first 12 weeks, followed by 12 weeks of dupilumab alone. The study aims to assess the improvement in skin condition as measured by established clinical scores. The approach seeks to enhance treatment outcomes for individuals suffering from this chronic skin condition.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with moderate to severe atopic dermatitis.
Not a fit: Patients who have previously been treated with dupilumab or have a history of photosensitivity may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the management of atopic dermatitis, leading to better skin health and quality of life for patients.
How similar studies have performed: Other studies have shown promising results with dupilumab for atopic dermatitis, indicating that this combined approach may also be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female adult ≥ 18 years of age; * Diagnosis of moderate to severe atopic dermatitis as defined at baseline by: * EASI score of 16 or greater, * IGA score of 3 or greater * BSA of 10% or greater, Exclusion Criteria: * Subjects with previous exposure to dupilumab. * Known or suspected hypersensitivity to dupilumab or any of its excipients. * History of photosensitivity.
Where this trial is running
East Windsor, New Jersey
- Eczema Treatment Center of New Jersey — East Windsor, New Jersey, United States (RECRUITING)
Study contacts
- Study coordinator: Elise Nelson
- Email: enelson@windsordermatology.com
- Phone: 6094434500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Atopic Dermatitis